LGD-4033 (Ligandrol): Scientific Profile
Publicado el · Actualizado el
Non-steroidal selective androgen receptor modulator (SARM), investigated for its tissue selectivity in musculoskeletal tissue for the study of atrophy reduction in experimental models.
LGD-4033, also identified in research literature as Ligandrol, is a non-steroidal androgen receptor ligand of high affinity and potency. Its development has focused on clinical research to address processes of muscle atrophy and bone weakness, demonstrating in study models a superior selectivity toward muscle and skeletal tissue compared with secondary androgenic organs such as the prostate.
In research settings, this compound acts by selectively binding to the androgen receptor (AR), which induces significant anabolism without the pharmacokinetic ramifications of conventional anabolic steroids. The collected data suggest that administration in animal models and experimental phases promotes an increase in protein synthesis and in bone mineral density.
The pharmacological profile of LGD-4033 shows a prolonged half-life, which allows consistent dosing in research protocols. Its ability to influence indirect weight reduction through an increase in the basal metabolic rate derived from the increase in lean mass of the study subject has been documented.
Mechanism of action
LGD-4033 functions as a partial or full agonist of the androgen receptor depending on the target tissue. Unlike synthetic testosterones, it is not a substrate for 5-alpha reductase or aromatase, which prevents conversion to dihydrotestosterone (DHT) or estrogen. Its molecular structure allows selective activation of the gene transcription pathways responsible for the growth of striated tissue and the strengthening of the bone matrix, minimizing activity in sebaceous glands and reproductive tissues.
Mechanism summary
Selective androgen receptor agonist with high tissue affinity toward skeletal muscle and bone, avoiding enzymatic conversion to estrogenic metabolites.
Clinical Studies (4)
- Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples Detected with or without Other Xenobiotics (Kwiatkowska D et al. · Molecules (Basel, Switzerland) · 2023) PMID 37764261.
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report (Cardaci TD et al. · Experimental physiology · 2022) PMID 36303408.
- Ligandrol (LGD-4033)-Induced Liver Injury (Barbara M et al. · ACG case reports journal · 2020) PMID 32637435.
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. (Basaria S, et al. · J Gerontol A Biol Sci Med Sci · 2013) PMID 22459616.
Warnings
LGD-4033 (Ligandrol) is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- Product exclusively for use in laboratory research
- Requires monitoring of lipid and hepatic profiles during the study
- Models with a history of hepatotoxicity
- Research subjects with androgen-sensitive neoplasms
- Pregnant or lactating models due to potential teratogenicity
Technical data
- CAS
- 1165910-22-4
- Molecular formula
- C14H12F6N2O
- Molecular weight
- 338.25 Da
- Compound type
- sarm
- Storage
- 15-25°C in a dry place
- Shelf life (lyophilized)
- 24 months
- Shelf life (reconstituted)
- Not applicable (Solid presentation)
- Light-sensitive
- No
Available for research
LGD-4033 (Ligandrol) is available as a research reagent (RUO):
Frequently asked questions about LGD-4033 (Ligandrol)
What is LGD-4033 (Ligandrol)?
Non-steroidal selective androgen receptor modulator (SARM), investigated for its tissue selectivity in musculoskeletal tissue for the study of atrophy reduction in experimental models.
What is the mechanism of action of LGD-4033 (Ligandrol)?
Selective androgen receptor agonist with high tissue affinity toward skeletal muscle and bone, avoiding enzymatic conversion to estrogenic metabolites.
What is LGD-4033 (Ligandrol) researched for?
In preclinical research, LGD-4033 (Ligandrol) is studied mainly in: Research on the preservation of lean mass; Study of the improvement in bone mineral density; Modulation of muscle strength in atrophy models. Material exclusively for scientific research.
What are the chemical properties of LGD-4033 (Ligandrol)?
Molecular formula C14H12F6N2O; molecular weight 338.25 Da; CAS number 1165910-22-4.
How is LGD-4033 (Ligandrol) stored?
Storage conditions: 15-25°C in a dry place; lyophilized stability: 24 months; once reconstituted: Not applicable (Solid presentation).
What routes of administration are studied for LGD-4033 (Ligandrol)?
In research models the following are described: Oral. Use is exclusively for scientific research.